The use of autologous peripheral blood stem cells as a hemopoietic support during polychemotherapy of children with soft tissue sarcomas.

Intensification of cycle polychemotherapy in disseminated tumors considerably improves the efficiency of complex treatment. Reinfusion of peripheral blood stem cells as a factor of replacement treatment during hemopoietic suppression or disorders is now becoming more and more promising.

[Blood stem cell transplantation in pediatric oncology].

Large-dose chemotherapy (LDCT) with auto- and allogenic transplantation of blood stem cells (BSC) in pediatric oncology remains so far the last hope for many patients. The number of such procedures made in Europe increases by 10% every year. At the same time many issues of the place and role of transplantation in pediatric oncology remains unclear.

[Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children].

The authors examined 8 patients with pretreated relapsing or resistant solid tumors (Wilms'--4, rhabdomyosarcoma--3, synovial sarcoma--1) who received 16 courses of chemotherapy: iphosphamide, 1800 mg/m2/day (days 1-5), vepeside, 100 mg/m2/day (days 1-5), and carboplatin 500 mg/m2/day (day 1) (IVC) and 18 courses of therapy wherein iphosphamide was replaced by cyclophosphanum, 400 mg/m2/day (days 1-5) (CVC). The patients received 2-4 induction courses (n = 18) and 1-5 consolidation courses (n = 16) with reinfusion of peripheral stem cells (PSC). All PSC separations were performed after the first or second courses of IVC/CVE.

[Significance of therapeutic pathomorphosis in the treatment and prognosis of osteogenic sarcoma in children].

To decide the problem of adequacy of preoperative treatment and postoperative special therapy, it is necessary to determine the degree of therapeutic pathomorphosis of primary osteogenic sarcoma. According to the materials of the children's clinic of the All-Union Cancer Research Center, USSR AMS, the degree of impairment is dependent on the size of the neoplasm, nature of the treatment and the x-ray-morphological variant. In a group of patients given preoperative chemoradiation treatment for degrees III and IV of therapeutic pathomorphosis, the 5-year survival amounted to 37.